Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cangene, a Canadian biotechnology company, has been awarded a C$17 million contract to supply Vaccinia Immune Globulin Intravenous to the UK Department of Health.
Subscribe to our email newsletter
Vaccinia Immune Globulin is a hyperimmune product to be used in treating and preventing a type of severe reaction that may be brought on by administration of the smallpox vaccine, and is considered to be an important component of smallpox vaccination programs.
Cangene expects to complete delivery of this order by the end of its 2006 fiscal year.
“As well as some smaller orders, this is the third significant government purchase of this product, which was recently approved by the US Food and Drug Administration,” said Dr John Langstaff, president and chief executive officer of Cangene. “As countries around the world consider implementing smallpox vaccination or stockpiling programs, the market for this product could grow”.
Cangene, in conjunction with its sales agents, is also in discussions with other foreign governments regarding a supply of VIG.